Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This research is being done to assess the therapeutic efficacy and safety of a promising
(venetoclax and decitabine) versus conventional "7+3"chemotherapy in induction young patients
with acute myeloid leukemia.
This study involves the following:
Venetoclax and decitabine (investigational combination) Cytarabine and idarubicin (per
standard of care)